Piper Sandler analyst Edward A. Tenthoff raised the firm’s price target on CytomX Therapeutics (CTMX) to $5 from $2.50 and keeps an Overweight rating on the shares after the company reported positive initial Phase I CX-2051 data in 3rd-line+ metastatic colorectal cancer. The results compare favorably to currently approved agents. Importantly, CytomX’s masking technology allowed for a clean safety profile with no Grade 4+ TRAEs. If the early efficacy signal holds, Piper expects CytomX will meet with FDA and initiate a potentially registrational Phase II study in the first half of 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Promising Clinical Data and Safety Profile Lead to Buy Rating for CytomX Therapeutics’ CX-2051
- CytomX Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- CytomX Therapeutics Secures $93.4 Million Through Stock Sale
- 3 Penny Stocks to Watch Now, 5/13/25
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue